Trials / Completed
CompletedNCT00091624
A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)
A Phase I Study of DVd +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 77 (actual)
- Sponsor
- Celgene Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase I Study of CC-5013 in combination with Doxil, Vincristine and Decadron (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CC-5013 |
Timeline
- Start date
- 2003-03-01
- Primary completion
- 2007-09-01
- Completion
- 2007-09-01
- First posted
- 2004-09-15
- Last updated
- 2016-12-01
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00091624. Inclusion in this directory is not an endorsement.